News - Vyvanse, Neurological

Filter

Current filters:

VyvanseNeurological

Popular Filters

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

12-06-2014

Ireland-headquartered drugmaker Shire says it has agreed to a written request by the US Food and Drug…

NeurologicalPharmaceuticalRegulationResearchShireUSAVyvanse

Shire will drop MDD indication for Vyvanse after failed endpoints in Ph III

07-02-2014

Shares of Ireland-headquartered Shire fell 2.4% to £30.67 in early trading, after the company presented…

NeurologicalPharmaceuticalResearchShireVyvanse

Added benefit of lisdexamfetamine not proven, says German watchdog

03-09-2013

Ireland-headquartered Shire's (LSE: SHP) Elvanse (lisdexamfetamine dimesylate) demonstrated no added…

ElvanseEuropelisdexamfetamine dimesylateNeurologicalPharmaceuticalPricingRegulationShireVyvanse

US FDA adds new indication for Shire's ADHD drug Vyvanse; 1st-qtr results

02-05-2013

Ireland-headquartered Shire (LSE: SHP) says that the US Food and Drug Administration has approved its…

FinancialNeurologicalNorth AmericaPharmaceuticalRegulationShireVyvanse

Shire agrees to settlement with US government over ADHD drug marketing

04-02-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said on Friday that it has reached an agreement in principle…

Adderall XRDaytranaFinancialLegalNeurologicalNorth AmericaPharmaceuticalShireVyvanse

Positive response from European regulatory procedure supports Shire's Elvanse for ADHD

18-12-2012

Ireland headquartered Shire (LSE: SHP) yesterday announced a positive outcome from the European Decentralized…

ElvanseEuropelisdexamfetamine dimesylateNeurologicalPharmaceuticalRegulationShireTyvenseVyvanse

FDA accepts Shire's sNDA for Vyvanse as maintenance treatment

12-09-2012

Ireland-headquartered drugmaker Shire (LSE: SHP) that the US Food and Drug Administration has accepted…

NeurologicalNorth AmericaPharmaceuticalRegulationShireVyvanse

Efficacy of Shire's Vyvanse maintained in ADHD adolescents after at least six months

24-05-2012

A significantly lower proportion of subjects experiencing treatment failure whilst receiving UK specialty…

NeurologicalPharmaceuticalResearchShireVyvanse

Shire forecasts strong 2012 EPS growth on record 2011 sales; Vyvanse news

10-02-2012

Shire (LSE: SHP), the UK’s third-largest drugmaker, posted a pleasing set of financial for full-year…

FinancialNeurologicalNorth AmericaPharmaceuticalRegulationShireVyvanse

Global ADHD market set to grow at a CAGR of 8% to 2018

14-12-2011

The global attention deficit hyperactivity disorder (ADHD) therapeutics market was valued at $3.86 billion…

DaytranaGlobalIntunivMarkets & MarketingNeurologicalPharmaceuticalShireVyvanse

Back to top